| abstract |
The present invention belongs to the field of medical chemistry, and relates to an antitumour pharmaceutical composition with two active components and the use thereof. In particular, the pharmaceutical composition to which the present invention relates comprises a first independent group of active ingredients and a second independent group of active ingredients, wherein the first group of active ingredients comprises two or three ingredients of the following three ingredients A, B and C: A. dipyridamole and/or pharmaceutically acceptable derivatives thereof; B. ubenimex and/or pharmaceutically acceptable derivatives thereof; C. dexamethasone and/or pharmaceutically acceptable derivatives thereof. The second group of active ingredients comprises one or more ingredients selected from paclitaxel, adriamycin, cisplatinum, mitomycin, fluorouracil, gemcitabine, capecitabine and tyrosine kinase inhibitor; optionally, the pharmaceutical composition also comprises a pharmaceutically acceptable carrier or excipient. The antitumour pharmaceutical composition in the present invention acts on multiple targets and multiple paths, which has a clear and significant antitumour effect. |